Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 13/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 4/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | BLK | P51451 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16385269 | 0.77 | — | — | |
| SCHEMBL10138954 | 0.77 | — | — | |
| SCHEMBL19617268 | 0.75 | GABRR1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL21879983 | 0.75 | KRAS (0.35) | JAK3FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL27426687 | 0.75 | CHRNB2 (0.45) | — | |
| SCHEMBL19617869 | 0.75 | GABRR1 (0.32) | — | |
| SCHEMBL4243520 | 0.75 | GABRR1 (0.32) | — | |
| SCHEMBL4243523 | 0.75 | GABRR1 (0.32) | — | |
| SCHEMBL19617872 | 0.75 | GABRR1 (0.32) | — | |
| SCHEMBL4243525 | 0.75 | GABRR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-15 | — | — | US | disclosed |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-15 | — | — | US | disclosed |
| US-20210395234-A1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | KRAS, NRAS, HRAS | JAK3 1279/4885FGFR1 748/4885FGFR2 592/4885 |
| US-20210395234-A1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | HDAC11, RCOR3, BICRA | JAK3 35/4885FGFR1 1001/4885FGFR2 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.